OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q1 2021 Results - Earnings Call Transcript

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -31.82% and -50.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) Reports Q1 Loss, Misses Revenue Estimates

Shares of OpGen (NASDAQ:OPGN) moved higher by 1.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 16.28% year over year to ($0.50), which missed the estimate of ($0.24).

Recap: OpGen Q1 Earnings

Conference call to be held at 8:30 a.m. Eastern Time today

OpGen Reports First Quarter 2021 Financial Results and Provides Business Update

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know

GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 13, 2021. OpGen's management team will host a live conference call and audio webcast at 8:30 a.m. Eastern Time to discuss the Company's financial results and provide an update on business activities.

OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time

GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is being extended beyond the second-year expansion phase by another six months through September 30, 2021.

OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections

Experts presented the results of their Unyvero studies and demonstrated:

OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -20.69% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates (Revised)

OpGen's (OPGN) CEO Oliver Schacht on Q4 2020 Results - Earnings Call Transcript

Conference call to be held at 4:30 p.m. Eastern Time today

OpGen Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

OpGen (NASDAQ:OPGN) unveils its next round of earnings this Thursday, March 25. Get prepared with Benzinga's ultimate preview for OpGen's Q4 earnings.

OpGen's Earnings Outlook

GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Thursday, March 25, 2021. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities.

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020

The stock price of OpGen Inc (NASDAQ: OPGN) is trading at over 40% pre-market. This is why it happened.

OPGN Stock Price Increases Over 40% Pre-Market: Why It Happened

Immunovant Inc

Anchiano Therapeutics Ltd - ADR

Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.

Why Immunovant, Anchiano, OpGen Are Rallying Today

OpGen (OPGN) stock is flying high on Monday following results from a study published in a peer-reviewed publication concerning coronavirus. The post OPGN Stock: 9 Things for OpGen Investors to Know as Shares Skyrocket appeared first on InvestorPlace.

OPGN Stock: 9 Things for OpGen Investors to Know as Shares Skyrocket

The stock price of OpGen Inc (NASDAQ: OPGN) has increased by over 10% pre-market. This is why it happened.

OPGN Stock Price Increases Over 10% Pre-Market: Why It Happened

Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients

OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia

The stock price of OpGen Inc (NASDAQ: OPGN) has increased by over 12% pre-market. This is why it happened.

OPGN Stock Price Increases Over 12% Pre-Market: Why It Happened

GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that it has recently received regulatory approval of the Curetis Unyvero System as an in vitro diagnostics (IVD) instrument system in China from the Chinese authorities (National Medical Products Administration, NMPA). The Medical Device Registration Certificate has been issued under the Registration number 20213220019.

OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System

Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data

OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing

GAITHERSBURG, Md., Jan. 13, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total pro-forma preliminary unaudited revenue (including revenue from discontinued operations) for OpGen in 2020 was approximately $5.2 million, compared to about $6.0 million in 2019. Fourth quarter 2020 revenue for OpGen was approximately $1.3 million compared to $ 0.8 million in Q4-2019. The company expects to provide fourth quarter 2020 and full year 2020 financial results during its upcoming earnings call in March 2021. OpGen's cash position as of December 31, 2020 was approximately $13.3 million, an increase from $2.7 million in 2019.

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that its subsidiary Curetis GmbH has entered into a distribution agreement with Annar Health Technologies (“Annar”) for Colombia. Annar, headquartered in Bogotá, is Colombia's leading diagnostics distributor that is already working with numerous renowned global IVD manufacturers.

OpGen Subsidiary Curetis and Annar Enter into Unyvero Distribution Partnership for Colombia

Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of its growth  

OpGen Announces Planned Leadership Transition at Next Generation Sequencing and Bioinformatics Subsidiary Ares Genetics

Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing

News for OpGen Stock (OPGN)